Professor Charles Swanton completed his PhD in 1998 at the Imperial Cancer Research Fund Laboratories on the University College London MBPhD programme before completing his medical oncology and Cancer Research UK funded post-doctoral clinician scientist training in 2008. Charles was appointed Medical Research Council and Cancer Research UK senior clinical research fellow and Group Leader of the Translational Cancer Therapeutics laboratory at the CR-UK London Research Institute in 2008 focusing on personalised cancer medicine through an understanding of mechanisms of drug resistance, intratumour heterogeneity and genomic instability. He combines his laboratory research with clinical duties focused on biological mechanisms of drug resistance in lung and breast cancer. Charles worked as a consultant medical oncologist at the Royal Marsden Hospital with an interest in early phase drug development for the treatment of specific subtypes of metastatic solid tumours (2008-2011). Charles has had lead or corresponding author publications in Nature, Cancer Cell, PNAS, Lancet Oncology and The New England Journal of Medicine. Charles is a member of several translational research scientific committees including AICR and Cancer Research UK Sciences Committee. He was made Fellow of the Royal College of Physicians in April 2011 and was appointed to the Chair in Personalised Cancer Medicine at the University College London Cancer Institute and Consultant Medical Oncologist at UCL Hospitals in November 2011.

The Lorne Genome conference gratefully acknowleges the support of EACR